NCT05877872 Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma
| NCT ID | NCT05877872 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Sun Yat-sen University |
| Condition | Nasopharyngeal Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 424 participants |
| Start Date | 2023-05-20 |
| Primary Completion | 2029-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 424 participants in total. It began in 2023-05-20 with a primary completion date of 2029-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare efficacy of two different resection extension in patients with resectable recurrent nasopharyngeal carcinoma after induction chemotherapy. The main question it aims to answer is that whether tumor regress areas after induction chemotherapy required complete resection. Patients will be randomly assigned to receive reduced-target resection or full-target resection after induction chemotherapy. Researchers will compare these two groups to see if the efficacy of reduced-target resection is not inferior to full-target resection.
Eligibility Criteria
Inclusion Criteria: 1. The recurrence time is more than 6 months from the end of radiotherapy. 2. Histologically confirmed recurrent nasopharyngeal carcinoma. 3. Resectable nasopharyngeal diseases: recurrent T1 (the tumor is confined in nasopharynx, oropharynx and/or nasal cavity without parapharyngeal involvement); recurrent T2 (the tumor is confined in the superficial parapharyngeal spacer and is more than 0.5cm far from the internal carotid artery) and recurrent T3 (the tumor is confined in the base wall of the sphenoid sinus and is more than 0.5cm far from the internal carotid artery and cavernous sinus) (according to the 8th edition of American Joint Committee on Cancer (AJCC) staging system for nasopharyngeal carcinoma). If the tumor invaded the internal carotid artery, or the instance from the internal carotid artery was less than 0.5cm, but the invasion area did not exceed the external edge of the internal carotid artery, the patients could be enrolled after internal carotid artery pretreatment (including internal carotid artery embolization or stent implantation). 4. After 3 cycles induction chemotherapy (Platinum based chemotherapy \[gemcitabine/paclitaxel and platinum\] and immunotherapy\[PD-1/PD-L1 antibody\] or a GAP regmen\[gemcitabine, Apatinib and immunotherapy\[PD-1/PD-L1 antibody\]), patients achieved at least PR according to RECIST criteria, and the reduction of pSTV after induction chemotherapy more than 50%. 5. Given written informed consent. Exclusion Criteria: 1. Karnofsky Performance Status (KPS) ≤70. 2. Has severe medical disorder, important organ dysfunction, and/or a substantial history of mental illness. 3. Tumor confined to the roof or the posterior wall of nasopharynx, without expected benefit from reduced-target resection. 4. Unresectable recurrent regional lymph node diseases (recurrent N1-3) with prevertebral fascia, cervical vertebrae, or common/internal carotid artery involvement (according to the 8th edition of AJCC staging system). 5. Clinically diagnosed with metastatic NPC. 6. Has known subjects with other malignant tumors (except for cured skin basal cell carcinoma or cervical carcinoma in situ). 7. Received a systematic or local glucocorticoid therapy within 4 weeks of planned start of study treatment. 8. Suffered from diseases need long-term treatment with immunosuppressive drugs, or required systematic or local glucocorticoid therapy with immunosuppressive doses. Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) agent. 9. Has active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy). Patients with skin disease that doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia) will be allowed to enroll. 10. Has a known history of human immunodeficiency virus (HIV), has hepatitis B surface antigen (HBsAg) positive with hepatitis B virus (HBV) DNA copy number of ≥1000cps/ml or hepatitis C virus (HCV) antibody positive. 11. Has received a live vaccine within 4 weeks of planned start of study treatment. Pregnancy or breast feeding. 12. Cannot complete regular follow-up.
Contact & Investigator
Ming-Yuan Chen, MD, PhD
PRINCIPAL INVESTIGATOR
Sun Yat-sen University
Frequently Asked Questions
Who can join the NCT05877872 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Nasopharyngeal Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05877872 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 424 participants.
Is NCT05877872 currently recruiting?
Yes, NCT05877872 is actively recruiting participants. Contact the research team at chmingy@mail.sysu.edu.cn for enrollment information.
Where is the NCT05877872 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT05877872 clinical trial?
NCT05877872 is sponsored by Sun Yat-sen University. The principal investigator is Ming-Yuan Chen, MD, PhD at Sun Yat-sen University. The trial plans to enroll 424 participants.